Alivia Specialty LLC
Rate Outlier
Billing above the 90th percentile across multiple procedure codes simultaneously.
Billing above the 90th percentile for 26 procedure codes: J9271 at 2.0× median, J9035 at 105.3× median.
Statistical flags are not proof of wrongdoing. Some entities (government agencies, home care programs) may legitimately bill at high rates. Hospitals, government entities, and large care organizations may legitimately bill at higher rates due to patient acuity, overhead costs, or specialized services. Read our methodology.
Red Flags Explained
▼
Each flag represents a statistical test that identified unusual billing patterns. Here's what each flag on this provider means in plain English:
Rate Outlier
Rate Outlier means this provider charges above the 90th percentile for multiple different procedure codes simultaneously. While one high-cost code could reflect specialization, consistently high rates across many codes may indicate systematic overbilling.
These flags are statistical indicators only. Many flagged providers have legitimate explanations for their billing patterns. Learn more about our methodology.
Advanced Detection Signals
Additional statistical tests from advanced fraud detection methods
These signals use advanced statistical methods including digit distribution analysis, change-point detection, and market concentration metrics. Learn more.
Risk Assessment
Bills $4,600.53 per claim for J9035 (Injection, bevacizumab, 10 mg) — 105.3× the national median of $43.71.
Bills $2,675.47 per claim for J0897 (Injection, denosumab, one milligram) — 5.4× the national median of $493.25.
Bills $2,952.47 per claim for Q5107 — 3.6× the national median of $824.41.
Billing in the top 1% nationally for 11 procedure codes: J9035, J0897, J9358.
This is a statistical summary, not an accusation. See our methodology.
Total Paid
$189.0M
$188,981,224
Total Claims
105K
Beneficiaries
71K
1.5 claims/patient
Avg Cost/Claim
$2K
#493 of 618K providers by total spending(top <0.1%)
🔍 Analysis
Provider Overview
Alivia Specialty LLC is a Pharmacy Specialty Pharmacy provider based in Guaynabo, PR. From the 2018–2024 period, this provider received $189.0M in Medicaid payments across 105K claims.
Why This Matters
This provider received $189.0M in taxpayer-funded Medicaid payments — enough to fund healthcare for approximately 23,622 Medicaid beneficiaries for a full year at average per-enrollee costs.
Monthly Spending Trend
Yearly Spending
Procedure Breakdown
Cost per claim compared to national benchmarks
This provider bills for 30 distinct procedure codes. The top code (J9271 (Injection, pembrolizumab, 1 mg)) accounts for 31% of total spending.
Injection, pembrolizumab, 1 mg
$58.9M
6K claims · 31.1%
Injection, bevacizumab, 10 mg
$19.0M
4K claims · 10.0%
$14.6M
2K claims
$8,999.70
$3,562.28
Nivolumab (Opdivo) injection, 1 mg
$14.6M
2K claims · 7.7%
$14.1M
2K claims
$5,938.10
$3,571.19
Injection, pertuzumab, one milligram
$14.1M
2K claims · 7.5%
$9.4M
2K claims
$4,690.51
$1,942.13
Injection, trastuzumab, ten milligrams
$9.4M
2K claims · 5.0%
Injection, denosumab, one milligram
$8.3M
3K claims · 4.4%
$7.3M
715 claims · 3.9%
$6.2M
1K claims · 3.3%
$5.7M
2K claims · 3.0%
$5.4M
540 claims · 2.8%
$4.6M
2K claims · 2.4%
$4.0M
107 claims · 2.1%
$3.9M
528 claims · 2.0%
$3.6M
1K claims · 1.9%
$3.5M
446 claims · 1.9%
$3.5M
520 claims · 1.8%
$2.4M
473 claims
$5,136.57
$2,280.20
Injection, octreotide, depot form, intramuscular, one milligram
$2.4M
473 claims · 1.3%
$2.4M
780 claims · 1.3%
$1.5M
221 claims · 0.8%
$1.3M
1K claims
$906.14
$470.36
Injection, onabotulinumtoxinA, 1 unit
$1.3M
1K claims · 0.7%
$1.3M
94 claims · 0.7%
$1.0M
76 claims · 0.6%
$966K
146 claims
$6,616.75
$4,027.41
Injection, vedolizumab, one milligram
$966K
146 claims · 0.5%
$795K
97 claims · 0.4%
$794K
238 claims · 0.4%
$517K
2K claims · 0.3%
$442K
1K claims
$433.82
$367.29
Injection, fulvestrant, twenty-five milligrams
$442K
1K claims · 0.2%
$428K
599 claims · 0.2%
$360K
2K claims · 0.2%
$318K
5K claims · 0.2%
Similar Providers
Other top providers in Pharmacy Specialty Pharmacy